Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 7/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7028959 | 0.89 | CRHR1 (0.46) | CRHR1 | |
| SCHEMBL7032138 | 0.79 | CRHR1 (0.46) | CRHR1 | |
| SCHEMBL7032751 | 0.79 | — | — | |
| SCHEMBL6355669 | 0.79 | CRHR1 (0.45) | CRHR1 | |
| SCHEMBL7033052 | 0.79 | ERBB2 (0.42) | — | |
| SCHEMBL7036941 | 0.78 | — | — | |
| SCHEMBL7034204 | 0.74 | — | — | |
| SCHEMBL6082265 | 0.74 | — | — | |
| SCHEMBL6082471 | 0.74 | — | — | |
| SCHEMBL6082260 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6974808-B2 | CRF receptor antagonists and methods relating thereto | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-13 | — | — | US | disclosed |
| US-20020049207-A1 | CRF receptor antagonists and methods relating thereto | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-04-25 | — | — | US | disclosed |
| US-6352990-B1 | A METHOD OF TREATING ANXIETY AND DEPRESSION IN A WARM-BLOODED ANIMAL AND TREATMENT OF STROKES | BRISTOL-MYERS SQUIBB COMPANY | 2002-03-05 | — | — | US | disclosed |
| EP-0970082-A2 | BIAZACYCLIC CRF ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998035967-A2 | BIAZACYCLIC CRF ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 1998-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049207-A1 | CRF receptor antagonists and methods relating thereto | CRHR1, CRH, CRHR2 | CRHR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.